Search results
14 gru 2017 · ASP8273 demonstrated antitumor activity in patients with EGFR-mutant lung cancers after prior treatment with EGFR TKIs. This study identified the ASP8273 RP2D to be 300 mg daily based on pharmacokinetics, pharmacodynamics, safety, and antitumor activity; the MTD was not established.
1 lip 2019 · The current study examines the efficacy, safety, and tolerability of ASP8273 versus erlotinib or gefitinib in patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations not previously treated with an EGFR inhibitor.
15 gru 2017 · ASP8273 is a third-generation EGFR TKI with antitumor activity in preclinical models of EGFR-mutant lung cancer that targets mutant EGFR, including EGFR T790M. Experimental Design: In this multicohort, phase I study ( NCT02113813 ), escalating doses of ASP8273 (25-500 mg) were administered once daily to non-small cell lung cancer (NSCLC ...
The current study examines the efficacy, safety, and tolerability of ASP8273 versus erlotinib or gefitinib in patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations not previously treated with an EGFR inhibitor.
20 maj 2016 · Described here are the preliminary antitumor effects of the RP2D in EGFR mutation-positive non-small cell lung cancer (NSCLC) previously treated with an EGFR TKI (most patients received ≥ 1 prior treatment) in 2 study populations: all subjects and subjects with T790M.
4 lip 2018 · Epidermal growth factor receptor (EGFR)‐activating mutations confer sensitivity to tyrosine kinase inhibitor (TKI) treatment for non‐small‐cell lung cancer (NSCLC). ASP8273 is a highly specific, irreversible, once‐daily, oral, EGFR TKI that inhibits both activating and resistance mutations.
ASP8273 was administered orally once daily (QD) and all patients were assessed for AEs, PK and preliminary anti-tumor activity. Dose-escalation and MTD estimation were conducted based on Bayesian-CRM.
